Literature DB >> 26537926

LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease.

Sandra Benito1, Alicia Sánchez2, Nora Unceta1, Fernando Andrade3, Luis Aldámiz-Echevarria3, M Aránzazu Goicolea1, Ramón J Barrio4.   

Abstract

Chronic kidney disease (CKD) is a major epidemiologic problem which causes several disturbances in adults and in pediatrics. Despite being a worldwide public health problem, information available for CKD in the pediatric population is scarce. For that reason, an ion-pair reversed-phase liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) method has been developed and validated in order to analyze 16 amino acids, amino acid derivatives, and analogous compounds related to the arginine-creatine metabolic pathway that are suspicious of being increased or decreased in plasma from patients with CKD. The analytical method involved the addition of dithiothreitol, a reducing agent which reduces disulfide and thus giving total aminothiol concentration, as well as a simple precipitation of plasma proteins. Moreover, despite amino acids being usually derivatized to improve their retention time and to enhance their signal, for this method, an ion-pairing reagent was used, thus avoiding the need for derivatization. Subsequently, analysis of plasma from pediatric patients suffering from CKD and control pediatrics was carried out. As a result, glycine, citrulline, creatinine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) were significantly increased in patients with CKD, regardless of their creatinine level, whereas in addition to these compounds dimethylglycine was also increased when CKD patients had plasma creatinine concentrations above 12 μg mL(-1), thus all are suggested as potential biomarkers for renal impairment.

Entities:  

Keywords:  Arginine-creatine metabolic pathway; Biomarkers; Chronic kidney disease (CKD); LC-QTOF-MS; Plasma

Mesh:

Substances:

Year:  2015        PMID: 26537926     DOI: 10.1007/s00216-015-9153-9

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

1.  Serum Cystatin C Level Monitoring for Intervention Opportunity of CBP in Children with Severe Sepsis.

Authors:  Weikai Wang; Yi Qiang; Zhongbin Tao; Baowang Yang; Bin Yan; Xilong Chen; Ruifeng Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

2.  Targeted neurotransmitter metabolomics profiling of oleanolic acid in the treatment of spontaneously hypertensive rats.

Authors:  Ruixue Yu; Wenqing Yang; Dongmei Qi; Lili Gong; Chao Li; Yunlun Li; Haiqiang Jiang
Journal:  RSC Adv       Date:  2019-07-26       Impact factor: 4.036

3.  Targeted Metabolic Profiling of Methionine Cycle Metabolites and Redox Thiol Pools in Mammalian Plasma, Cells and Urine.

Authors:  Sidney Behringer; Victoria Wingert; Victor Oria; Anke Schumann; Sarah Grünert; Artur Cieslar-Pobuda; Stefan Kölker; Ann-Kathrin Lederer; Donald W Jacobsen; Judith Staerk; Oliver Schilling; Ute Spiekerkoetter; Luciana Hannibal
Journal:  Metabolites       Date:  2019-10-18

4.  Nitric Oxide Synthesis Metabolites-As Potential Markers in Chronic Kidney Disease in Children.

Authors:  Joanna Piechowicz; Andrzej Gamian; Ositadima Chukwu; Dorota Polak-Jonkisz
Journal:  Curr Issues Mol Biol       Date:  2022-08-07       Impact factor: 2.976

5.  Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy.

Authors:  Fanliang Zhang; Ruixue Guo; Wen Cui; Li Wang; Jing Xiao; Jin Shang; Zhanzheng Zhao
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 6.  New Insights from Metabolomics in Pediatric Renal Diseases.

Authors:  Simona Riccio; Maria Sole Valentino; Antonio Paride Passaro; Marica Izzo; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo; Anna Di Sessa
Journal:  Children (Basel)       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.